NSCLC adenocarcinoma
Oncology · 2015–2016
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nintedanib Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with adenocarcinoma histology in combination with docetaxel, after… | Mar 2016 | Not recommended | input received Lung Foundation Australia · Lung Cancer Foundation Australia |
| nintedanib Second-line treatment of locally advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma histology, in combination with… | Mar 2015 | Not recommended | none received |
Who spoke
Lung Foundation Australia · Lung Cancer Foundation Australia
What the PBS pays
$87M in government benefit over 2024–25, across 33,531 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| nintedanib | $87M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.